Hepatitis C Market Forecast 2032: FDA, EMA, PDMA Approvals, Epidemiology, Therapies, Clinical Trials and Companies by DelveInsight | BMS, Merck, Roche, Gilead Sciences, Johnson & Johnson, Abbvie
https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/26038163/hepatitis-c-market-forecast-2032-fda-ema-pdma-approvals-epidemiology-therapies-clinical-trials-and-companies-by-delveinsight-bms-merck-roche-gilead-sciences-johnson-johnson-abbvie/
$10 Billion Deal, page-12434
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $46.91M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $6.964K | 133.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 151165 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 127619 | 2 |
View Market Depth
| Last trade - 13.27pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.2¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 5.3¢ | 5.3¢ | 5.2¢ | 38302 | ||
| Last updated 11.25am 24/05/2024 ? | |||||
| BIT (ASX) Chart |